Hi Fourwins and DappaT. Well here's hoping for an update soon most likely in the 4C for VBS. TBH it's been very quiet here since the CR and I would have expected to hear that we've been ticked off for safety and well into recruitment, moving towards initiation of P1 by now but we will find out in a few weeks at most.
I was introduced by a Soph during the last raise which was well oversubbed. I'm in at $1.30ish.
What drew me was very solid results in lab in fobrosis along a range of verticals all with poor prognoses. If you assume our other stock and others are successful in chipping away at the big C then fibrosis is a really interesting area to work in. In terms of license / sale, lets see the notes from the company statey the've been in discussions re multiple licensing opportunities - hoping to learn more this 4C.
They also own a venture called Accugen which has developed IP and a platform to quickly and accurately quantify genes of interest, without the need for reference genes or standard curves http://www.accugen.com.au/about-us/. It seems this was IP developed / stumbled upon during Vectus core work. It seems to me that Accugen has potential as a spin-off or JV.
32m SOI and 66% owned by top 20.
Beyond that, waiting for new data!.
- Forums
- ASX - By Stock
- VBS
- Ann: Quarterly Activities Report & Appendix 4C
Ann: Quarterly Activities Report & Appendix 4C, page-19
-
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add VBS (ASX) to my watchlist
(20min delay)
|
|||||
Last
8.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.633M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
VBS (ASX) Chart |
Day chart unavailable